Free Daily Podcast Summary
Hims House: Daily Summaries Delivered
by Jonathan Stern
Hims House is the ultimate podcast for Hims & Hers investors. Hosted by Jonathan Stern and Patrick Lester, Hims House breaks down all the key questions shaping $HIMS — from telehealth and pharma to GLP-1s, compounding, and the future of healthcare. New episodes every week. himshouse.substack.com
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- Yesterday52 min
Brazil's 2nd-largest telehealth CEO on how Hims & Hers should enter Brazil 🇧🇷
Thanks to our partner: Superpower - https://superpower.comIn episode 82, Jonathan Stern talks with Abrahão Fecury, co-founder and CEO of Eles & Elas, a Brazilian telehealth company built on the Hims playbook and now at about R$4.5 million (~$1 million USD) in annual revenue, growing about +10% a month. Weight loss is about 70% of that (compounded tirzepatide) at a 54% gross margin, with hair loss and mental health smaller and more profitable. Fecury walks through cash-pay pharmacies, Meta and WhatsApp customer acquisition, and how ANVISA's summer ban on Voy changed the category. We close with a discussion about Hims & Hers - where he says, if Hims wants to expand into Brazil, it should "absolutely buy" a telehealth in Brazil (like Voy or Eles & Elas) vs building everything itself. 00:00 - Sponsor: Superpower04:51 - Revenue of R$4.5 million (~$1 million USD)10:25 - Margins of each category13:35 - Brazil healthcare 10116:43 - 1 in 4 adults in Brazil has obesity19:22 - Meta Ads brings in 80% of customers24:30 - Why ANVISA banned Voy, then reversed it on August 528:32 - Voy "more than 10x Eles & Elas' revenue"30:57 - Generic semaglutide margin is only 5-10%34:26 - Lilly suing in Brazil too35:30 - Paraguay shenanigans40:38 - Hims should buy a telehealth to expand into Brazil48:34 - Other countries in LatAmDisclaimer: This podcast is for informational and entertainment purposes only. Nothing discussed should be considered financial, investment, or legal advice. Always consult with a qualified professional before making financial decisions.
- 1 weeks ago40 min
Finnrick CEO on gray market peptides, fake bodega vials, and China's manufacturing prowess
Thanks to our partner:Superpower - https://superpower.com
- 3 weeks ago30 min
OpenLoop CEO: the peptide gray market is 2-3x bigger than analyst estimates, likely $6-8 billion
Thanks to our partner:Superpower - https://superpower.comIn episode 80 of Hims House, Jonathan Stern talks with Dr. Jon Lensing, co-founder and CEO of OpenLoop, the white-label company that runs telehealth behind the scenes for other brands. Lensing started OpenLoop out of the University of Iowa's medical school and says the platform will see more than 8 million patients this year and treat more than a million a month, across 400-plus brands from telehealth companies to grocery stores, dating apps, and gyms. He said he thinks GLP-1s will become a default medication the way statins did for cholesterol: he expects 80% of people over 30 could be on them by 2035, and he thinks Andrew Dudum's path to $40-$50 a month cash-pay is directionally right, maybe lower. On peptides he thinks some could be legal to compound before year-end, but not all at once. And he sizes today's gray market at $6 to $8 billion. 00:00 - Sponsor: Superpower01:37 - The Shopify of virtual healthcare04:32 - OpenLoop serving 8M patients this year05:33 - MEDVi 07:08 - OpenLoop's January data breach08:13 - Consumerism in healthcare10:38 - 80% of people over 30 will be on GLP-1s16:22 - Peptides likely this year, but not all at once18:46 - Ready to launch peptides the day FDA allows21:17 - Peptide API from FDA green-listed vendors22:51 - Peptide gray market is $6 to $8 billion27:01 - AI data moatsDisclaimer: This podcast is for informational and entertainment purposes only. Nothing discussed should be considered financial, investment, or legal advice. Always consult with a qualified professional before making financial decisions.
- Sep 3, 202639 min
HIMS stock token hit $132 on Robinhood over the weekend due to ... $BONER coin?! 😳
Thanks to our partner:Superpower - https://superpower.com🚨 WARNING: This is not a typical Hims House podcast! I wanted to do this interview because what happened on Robinhood Chain this weekend directly affected $HIMS -- and I think Hims investors should at minimum understand what happened.Jonathan Stern talks with Eric, an Ethereum OG and the world's largest $BONER holder, and Yoni, co-founder of Long.xyz, about BONER — a memecoin on Robinhood Chain paired with the $HIMS stock token. BONER reached roughly 12,000 holders in five days and helped make Hims a top-15 Robinhood stock token. Then, with the NYSE closed and limited Hims tokens available on-chain, $HIMS briefly traded at $132 versus a $28.75 NYSE close. Token supply jumped from roughly 20,000 to 80,000 in 72 hours. Eric and Yoni both stress that BONER is highly speculative and could go to zero. But Eric's longer-term thesis is that every major tokenized stock could eventually develop its own memecoin community.00:00 - Sponsor: Superpower01:27 - Why should Hims investors care? 03:35 - 12K Boner holders in five days06:00 - Why buy Boner instead of the stock token14:31 - 99% of meme coins go to zero19:00 - Open pairing: Boner-Hims22:27 - $132 on chain vs $28.75 on the NYSE26:44 - Could this trigger a short squeeze?34:06 - Has anyone at Hims called?36:25 - Every major stock gets a meme coin communityDisclaimer: This podcast is for informational and entertainment purposes only. Nothing discussed should be considered financial, investment, or legal advice. Always consult with a qualified professional before making financial decisions.
- Sep 2, 202653 min
🚨 THE FTC SUES HIMS & HERS -- Full breakdown with Gaston Kroub
Thanks to our partner:Superpower - https://superpower.comJonathan Stern talks with Gaston Kroub, founding partner of K2K Law, registered patent attorney, and Hims House's resident legal expert on his third appearance, about the FTC's July 29 federal complaint against Hims & Hers. Kroub calls the filing a public "marketing document" aimed at a quick settlement and ranks three allegation buckets: health data sharing with Meta and Snap as the most exposure, hard cancellation under ROSCA (Restore Online Shoppers' Confidence Act) second, charging before a real consultation as the least dangerous. The case is in the Northern District of California before Judge Vince Chhabria; an overbroad sealing request triggered an order to show cause that was later lifted with a warning, and Hims' response is due Sept. 28 with an initial case management conference Oct. 30. They walk through Hims' defense lineup at BakerHostetler and Keker Van Nest & Peters, treat the $62.5M legal accrual as likely the low end of a settlement, and cover co-plaintiffs Utah and LA County. His likely path is a payment plus operational changes; absent a deal, litigation could run years, and he treats the Visa chargeback spike as a minor narrative risk.00:00 - Sponsor: Superpower01:35 - Complaint is a "marketing document"03:52 - He ranks the three buckets08:15 - Amazon Prime and Uber first11:53 - ROSCA stretched to health data17:12 - Northern District of California and Judge Chhabria19:44 - Overbroad sealing nearly got sanctions23:57 - BakerHostetler and Keker26:12 - The $62.5M legal accrual27:32 - A Motion to Dismiss costs six figures28:51 - $50M floor, nine-figure ceiling?30:31 - Utah and LA County33:06 - Pay, plus changes to the flows35:46 - Would Ro and Noom have to follow?38:00 - Why Hims, not Ro39:42 - Visa's chargeback watchlist43:03 - Worst case vs most likely scenarios48:41 - Next steps in the case51:23 - Change the flows now, or wait?Disclaimer: This podcast is for informational and entertainment purposes only. Nothing discussed should be considered financial, investment, or legal advice. Always consult with a qualified professional before making financial decisions.
- Aug 26, 20261h 0m
Bijan Salehizadeh - Eli Lilly's War on Compounded GLP-1s, Peptides, Retatrutide, and Hims vs Ro
Thanks to our partner:Superpower - https://superpower.comIn episode 77, Jonathan Stern talks with Dr. Bijan Salehizadeh -- physician and managing director of NaviMed Capital, former pharma venture investor, founding investor in Auris Health. Bijan holds no position in HIMS. The conversation opens on the FDA: why Heidi Overton is "moldable clay," her 30-40% confirmation odds, and why pharma prefers interim commissioner Kyle Diamantis. They then move to Eli Lilly's multi-front war on compounded GLP-1s, the ReviveRx suit, the effort to pull semaglutide and tirzepatide off the 503B bulks list, and Bijan's theory of a "grand bargain" trading compounding restrictions for Medicare pricing cooperation. He walks through the retatrutide biologic fight ahead of the September 24th appellate argument in Chicago, and why Hims' 76% gross margins are gone for good as branded dispensing grows. They close on peptides: Bijan has heard Category 1 rulemaking *could* come as soon as November, and he thinks the market could be 10x bigger than current estimates.00:00 - Sponsor: Superpower01:16 - No one knows anything about Heidi Overton (FDA nominee)06:29 - Eli Lilly's war on 503A pharmacies08:47 - The Lilly "grand bargain"13:49 - When compounding becomes a "new drug" 17:34 - Branded drugs crush margins21:51 - Hims management scorecard26:29 - Retatrutide reclassification fight35:10 - Suing the reta gray market vendors37:06 - Why the Wegovy pill is beating Foundayo40:56 - Europe is a second-tier market42:15 - Can LillyDirect beat telehealth?46:14 - Peptides Wild West50:51 - Category 1 by November?52:40 - Peptides market 10x bigger than estimates55:56 - Will Ro go public?58:34 - Bullish $HIMS long term Disclaimer: This podcast is for informational and entertainment purposes only. Nothing discussed should be considered financial, investment, or legal advice. Always consult with a qualified professional before making financial decisions.
- Aug 7, 202654 min
Enhanced Group CEO: Hot peptide summer is coming — but likely not till 2027
Thanks to our partner:Superpower - https://superpower.comMax's recent essays on peptides:https://maximilianbmartin.substack.com/p/six-peptides-one-signal-washingtonhttps://maximilianbmartin.substack.com/p/the-peptide-moment-is-here-enhancedIn episode 76 of Hims House, Jonathan Stern hosts Maximilian Martin, CEO of Enhanced Group ( $ENHA ), the newly public company behind the Enhanced Games and the Live Enhanced telehealth platform. Martin grades the inaugural games ten weeks out — 42 athletes, 21 personal bests, one world record, and $32M in contracted sponsorship — and argues the 40% stock price selloff that occurred after the Games is misplaced. He recounts his week in Washington D.C., around the FDA compounding advisory committee, where six of seven peptides were recommended, and explains why Enhanced will wait on FDA’s formal rulemaking to start selling peptides. He concedes peptides are essentially a “commodity”, so the edge has to come from brand and personalized protocols. Also covered: whether big pharma is quietly slowing things down, how big the market for peptides could be, and Enhanced’s recent supplements launch in 33 new countries. 00:00 - Sponsor: Superpower 01:38 - The Enhanced Games: an honest scorecard 06:35 - Why $ENHA stock fell 40% 10:13 - The athlete-led flywheel 11:52 - Why he flew to Washington for peptides 18:07 - Six of seven peptides recommended 20:21 - How long will FDA rulemaking take? 22:51 - Where the peptide moat actually is 30:16 - Is big pharma slowing down peptide approval?32:14 - Being first vs being best 40:33 - Could peptides be a $10B market in 2027? 46:00 - Enhanced now live in 33 new markets 50:25 - Life as a public company CEODisclaimer: This podcast is for informational and entertainment purposes only. Nothing discussed should be considered financial, investment, or legal advice. Always consult with a qualified professional before making financial decisions.
- Jul 27, 202659 min
🚨 FDA committee votes "YES" on 6 of 7 peptides — here's what happens next, with Dr. Alex Tatem
Thanks to our partner:Superpower - https://superpower.comIn episode 75 of Hims House, Jonathan Stern talks with Dr. Alex Tatem, a board-certified urologist who has worked with peptides for 12 years and paid his own way to Silver Spring, MD, to testify on all 7 peptides before the FDA's Pharmacy Compounding Advisory Committee. The panel overruled the FDA's own scientists and recommended six of seven for the 503A Bulks List — DSIP the lone no — and Tatem describes what the national media coverage missed: specifically, briefing documents that omitted the peptide data entirely. He explains why the recommendation isn't binding, why a final rule could take months or years, and how limits on route of administration could hollow out the win. On the business side: why Hims and Noom will wait for final rulemaking while smaller players roll the dice, the API landscape, and the market dynamics of BPC-157 once approved. 00:00 - Sponsor: Superpower01:37 - What it was like in the room of the FDA05:53 - Briefing documents OMITTED the data11:33 - The one "NO" vote17:33 - Why the win isn't binding21:33 - Rulemaking timeline: likely months or years24:19 - RFK vs the FDA bureaucracy28:06 - Who will sell peptides before final rulemaking31:34 - Hims likely won't 34:43 - Peptide marketing claims 40:18 - Every raw material (API) comes from China45:23 - BPC under $100 a month? 48:29 - Where was Ro?50:08 - The best argument *against* peptides55:12 - Peptides will be an economic gold rushDisclaimer: This podcast is for informational and entertainment purposes only. Nothing discussed should be considered financial, investment, or legal advice. Always consult with a qualified professional before making financial decisions.
Get Hims House summaries in your inbox
Free AI-powered daily recaps. Key takeaways, quotes, and mentions — in a 5-minute read.
Get Free Summaries →Free forever for up to 3 podcasts. No credit card required.
You Might Also Like
Listeners also like.
Health vs Hype with the American Medical Association
A medical expert debunks viral health trends and misinformation with science-backed insights from physicians.
Health Optimization Medicine Podcast
Experts discuss science-based strategies for health optimization, performance, and human potential through targeted interventions.
GSD Mode Podcast
Real estate professionals and entrepreneurs learn actionable strategies to grow their businesses through interviews and expert advice.
The Best One Yet
A daily 20-minute podcast breaking down the three key business stories with sharp, accessible takes.
Stock Movers
Short conversations analyzing today's biggest gainers and losers in global stock markets across major sectors.
Biohack-it
A weekly exploration of biohacking, holistic health, and science-driven strategies for optimizing physical and mental well-being.
The Health Revival Show
Explores gut health and hormone optimization through expert insights, practical tips, and real-life success stories.
Pharmacy Podcast Network
A podcast network featuring dozens of shows on pharmacy practice, policy, and innovation, with interviews across clinical and industry specialties.
The Compound and Friends
Expert analysis and candid discussions on business and investing trends with a rotating panel of financial professionals.
Prof G Markets
Daily market news and analysis on earnings, geopolitics, Big Tech, and AI with clear, no-jargon insights.
The BioHub - by Avetix
Conversations with leading biotech experts reveal the strategies and stories driving innovation in the biotechnology industry.
SHE MD
Obstetrician Dr. Thais Aliabadi and women’s advocate Mary Alice Haney discuss women’s health issues with experts and celebrity guests.
About Hims House
Hims House is the ultimate podcast for Hims & Hers investors. Hosted by Jonathan Stern and Patrick Lester, Hims House breaks down all the key questions shaping $HIMS — from telehealth and pharma to GLP-1s, compounding, and the future of healthcare. New episodes every week. himshouse.substack.com
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from Hims House in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's Hims House daily summary?
It's a free AI-powered email that summarizes new episodes of Hims House as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the Hims House podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official Hims House product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by Jonathan Stern.
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts. Upgrade to Pro for 15, or Premium for 50. Browse our full catalog at /podcasts.
What topics does Hims House cover?
Hims House covers topics including Business, Investing. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting Hims House summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.